Exicure, Inc. (NASDAQ:XCUR) Sees Large Decrease in Short Interest

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a significant drop in short interest during the month of May. As of May 15th, there was short interest totaling 32,290 shares, a drop of 38.4% from the April 30th total of 52,380 shares. Based on an average daily volume of 13,641 shares, the short-interest ratio is currently 2.4 days. Approximately 1.1% of the company’s stock are sold short.

Exicure Stock Performance

XCUR stock opened at $3.11 on Wednesday. The firm has a market capitalization of $19.81 million, a price-to-earnings ratio of -2.01 and a beta of 3.53. The firm has a 50 day moving average price of $3.61 and a 200-day moving average price of $4.41. Exicure has a 52-week low of $2.63 and a 52-week high of $10.80.

Exicure (NASDAQ:XCUR) last announced its quarterly earnings results on Friday, May 29th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($18.60) by $18.31.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Exicure from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 28th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.